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ABSTRACT
Extracellular vesicles (EVs) are central to intercellular communication and play an important role in
cancer progression and development. Osteosarcoma (OS) is an aggressive bone tumour, char-
acterized by the presence of malignant mesenchymal cells. The specific tumour-driving genetic
alterations that are associated with OS development are currently poorly understood.
Mesenchymal stem cells (MSCs) of osteogenic lineage have been postulated as likely candidates
as the cells of origin for OS, thus indicating that MSCs and OS stroma cells may be related cell
types. Therefore, this study set out to examine the EV-mediated intercellular crosstalk of MSCs and
OS. MSCs and pre-osteoblasts were treated with OS-EVs at different time points, and the epige-
netic signature of OS-EVs was assessed by methylation analysis of LINE-1 (long interspersed
element) and tumour suppressor genes. In addition, surface markers and expression of specific
genes were also evaluated. Our data indicated that OS-EVs mediated LINE-1 hypomethylation in
MSCs, whereas an opposite effect was seen in pre-osteoblasts, indicating that MSCs but not pre-
osteoblasts were susceptible to epigenetic transformation. Thus, OS-EVs modulated the fate of
MSCs by modulating the epigenetic status, and also influenced the expression of genes related to
bone microenvironment remodelling. Overall, this study provided evidence that epigenetic reg-
ulation appears to be an early event in the transformation of MSCs during the development of OS.
Elucidating the mechanisms of EV-mediated communication may lead to new avenues for
therapeutic exploitation.
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Introduction
Osteosarcoma (OS) is the most common primary
heterogeneous malignant tumour of long bones
affecting children and adolescents. Though rela-
tively rare, it is still one of the highest causes of
cancer-related deaths in paediatric patients [1,2]. It
is characterized by increased osteoid production,
a strong tendency for recurrence and an extremely
high metastatic potential [3,4]. For the last three
decades, 5-year survival rates for metastatic and
recurrent OS is below 20% and has remained
unchanged [5]. Therefore, novel treatment
approaches are urgently needed. Identification of
tumour driving genetic alterations associated with
OS development is hindered due to the lack of
precursor lesions, presence of complex karyotypes,
high genetic instability, and lack of recurrent
genetic alterations in OS [6]. The cells of origin
for OS also remain unknown. Recent data have
suggested a hypothesis that under the influence
of certain environmental and epigenetic signals,
an MSC-derived osteogenic progenitor or an
undifferentiated MSC may be the cell of origin
for OS [7–10]. Thus, understanding the cellular
origin of OS will have direct implications on
improving treatment approaches through identifi-
cation of new therapeutic targets.
Extracellular vesicles (EVs) are membrane-
bound biologically active nano-vesicles found in
all bodily fluids. They are secreted by most cell
types that are involved in both physiological and
pathological conditions [11,12]. The complex and
specific cargo of EVs (lipids, proteins, mRNA,
microRNA and other non-coding RNA) as well
as their composition differ depending on their
CONTACT Sippy Kaur sippy.kaur@helsinki.fi Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, PO
Box 63, Helsinki 00014, Finland
*These authors contributed equally.
EPIGENETICS
2019, VOL. 14, NO. 4, 352–364
https://doi.org/10.1080/15592294.2019.1585177
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
cellular origin [13,14]. EVs mediate intercellular
communication through the bidirectional
exchange of their cargo with neighbouring cells.
They have been shown to induce epigenetic
changes by affecting the DNA methylation status
and change the phenotype of several recipient cell
types [15–17]. Further, it has been suggested that
EV-associated mRNA and proteins are involved in
epigenetic regulation, thus affecting the expression
of tumour promoting or suppressing genes [15].
Tumour-derived EVs are a driving force in the
transformation of MSCs [18–20]. However, the
influence of OS-derived EVs (OS-EVs) on the
epigenetic reprograming of MSCs and pre-
osteoblasts, specifically the global LINE-1 (long
interspersed element) methylation status, is still
largely unknown, and the mechanisms underly-
ing the conversion of normal MSCs into
tumour-favourable MSCs remain unclear [21].
Global LINE-1 hypomethylation is viewed as an
early event in normal cell transformation in
a wide range of cancers and benign neoplasms
[22]. However, conflicting data also exists
[23,24]. Addressing these questions may yield
new insights as to the cell of origin of OS, with
the prospect of finding and exploiting molecular
drivers underlying OS.
Thus, we examined the consequences of OS-EV
treatment on the epigenetic reprograming of
MSCs and pre-osteoblasts by analyzing their global
LINE-1 status and methylation analysis of selected
tumour suppressor genes. Taken together, our data
showed that OS-EVs mediated an epigenetic
response in MSCs, but not in pre-osteoblasts,
thus indicating that MSCs but not pre-osteoblast
were more susceptible to epigenetic transforma-
tion. There were no changes seen in the methyla-
tion status of tumour suppressor genes in MSCs.
As early indicators of transformation, OS-EV trea-
ted MSCs and pre-osteoblasts showed higher
expression of genes related to bone microenviron-
ment remodelling and also a significant upregula-
tion of intercellular adhesion molecule (ICAM1/
CD54). Thus, OS-EVs dictated the fate of MSCs by
modulating their epigenetic status. Overall, this
study provided evidence that epigenetic regulation
appears to occur early in the transformation of
MSCs.
Materials and methods
The workflow is described in Figure 1.
Cell lines and cell culture
Human osteosarcoma cell line 143B (HOS143b;
ATCC® CRL-8303™) was purchased from ATCC
and cultured according to the manufacturer’s
Figure 1. Flowchart of the study design. MSCs/pre-osteoblasts were treated with OS-EVs at different time points (TP 0, 3 and 7 days).
MSCs and OS-EVs were characterized by various methods. OS-EV treated MSCs/pre-osteoblasts samples were further analyzed for
DNA methylation, surface marker and gene expression.
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instructions. Briefly, cells were cultured in RPMI
Medium 1640 + GlutaMAX (Gibco Life
Technologies, ref. 61870–010 lot. 1896169),
supplemented with 1% antibiotics (100 U/ml peni-
cillin, 0.1 mg/ml streptomycin; Lonza ref. DE
17–602 E, lot. 5MB 068) and 10% foetal bovine
serum (FBS; Gibco Life Technologies, South
American ref. 10270106, lot. 42G8468K). Human
osteosarcoma line U2OS (ATCC® HTB-96™) cells
were cultured in maintenance media (MM) con-
sisting of Dulbecco’s modified Eagle’s medium/
Ham’s Nutrient Mixture F-12 with 1% L-alanyl-
L-glutamine (DMEM/F-12 1:1 GlutaMAX; Gibco
ref. 31331–028, lot. 1765999), 1% antibiotics and
10% FBS (Foetal Bovine Serum, South American
ref. 10270–106, lot. 42G8468K).
Adipose tissue was provided by the Department of
Plastic Surgery (Laser Tilkka Ltd, Finland). All tissue
donors (n = 6) were female, age range 32–55 years,
average 41 years; BMI range 22–29, average 25. The
study was carried out under approval of the ethical
committee of Helsinki and Uusimaa Hospital
District and with informed consent from the donors
(Ethical approval DNro: 217/13/03/02/2015). Human
adipose tissue mesenchymal stromal/stem cells (AT-
MSCs) were obtained from water-assisted lipotrans-
fer liposuction aspirates [25,] using mechanical and
enzymatic isolation as described previously [25].
Once AT-MSCs had adhered to the culture flask
surface, non-adherent populations were washed
away with PBS, and fresh culture media was added.
Cells were cultured in MM. Human bone marrow
MSCs (BM-MSCs) were received as a kind gift from
Assoc. Prof Susanna Miettinen (University of
Tampere). The BM-MSCs were expanded in MM
similarly to AT-MSCs.
AT-MSC characterization
AT-MSCs (n = 4) were characterized using BD
Accuri C6 flow cytometer (Becton Dickinson,
Franklin Lakes) to confirm the mesenchymal origin
of the cells. Allophycocyanin (APC)-conjugated
monoclonal antibodies against CD14 (clone:
M5E2), CD19 (clone: HIB19), CD34 (clone: 581),
CD45RO (clone: UCHL1), CD54 (clone: HA58),
CD73 (clone: AD2), CD90 (clone: 5E10), CD105
(clone: 266) and HLA-DR (clone: G46-6) (BD
Pharmingen, Becton Dickinson) were used.
Analysis was performed on 100,000 cells per sample
and the positive expression was defined as the level
of fluorescence greater than 99% of the correspond-
ing unstained cell sample [26].
Osteogenic differentiation assay
Osteogenically differentiated MSCs were termed
pre-osteoblasts. For pre-osteoblast differentiation,
MSCs were cultured for 14 days in osteogenic
media (OM). Briefly, cells were left to adhere for
24 h in MM and osteogenic differentiation was
induced using osteogenic media (MM) supple-
mented with 50 µM L-ascorbic acid 2-phosphate,
10 mM β-glycerophosphate disodium salt hydrate
and 5 nM dexamethasone (all Sigma-Aldrich).
Early osteogenic response was assessed by quanti-
tative alkaline phosphatase activity (qALP) assays
and mineralization was assessed using Alizarin
Red staining (ARS) as described previously [26]
after 3 weeks of osteogenic induction [27].
EV isolation and treatments
EV isolation
EV-depleted FBS was prepared by 19 h of ultra-
centrifugation at 100,000g using an SW28 rotor,
k-factor 246 (Beckmann-Coulter) +4°C. Only the
light-coloured top layers of the supernatant were
used in the subsequent analyses. Cell lines (HOS
and MSCs) were maintained in culture medium
containing FBS, but prior to EV harvesting, the
cells were switched into media containing EV-
depleted FBS for up to 72 h. Every 24 h up to
72 h, conditioned media (CM) was collected and
stored at −80°C. Fresh EV-depleted media was
added every time after collection of the cell cul-
tures. EVs collected from conditioned OS media
(OS-EVs) were extracted using ultracentrifuga-
tion at 100,000g for 2 h at +4°C to collect the EV
pellet, filtered in PBS (0.1µm filter) and then
ultracentrifugation was repeated. Isolated pellets
were suspended in filtered PBS and stored in low
protein binding microcentrifuge tubes (Protein
LoBind Tube, Eppendorf) at −80°C.
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Nanoparticle tracking analysis (NTA)
The EVs were analyzed by NTA to determine
vesicle concentration and size distribution using
(0.1 μm) DPBS to obtain the optimal detection
concentration of 106–109 particles/ml, and three
60 s videos were recorded using camera level 13.
The data was analyzed using NTA software 3.0
with the detection threshold 5 [27].
Transmission electron microscopy (TEM)
EV samples were prepared for EM and imaged as
described previously [27,28]. Briefly, samples
from 2–3 biological replicates were viewed with
transmission EM using Tecnai 12 (FEI
Company) operating at 80 kV. Images were
taken with Gatan Orius SC 1000B CCD-camera
(Gatan Inc.) with 4008 × 2672 px image size and
no binning.
Western blotting
Western blotting was performed as described pre-
viously [27] using antibodies against Hsp70 (70 kDa
heat shock protein, BD Biosciences, cat#554243,
1:100) CD63 (Lysosomal-Associated Membrane
Protein 3, BD Biosciences, cat#556019, 1:1000), cal-
nexin (Cell Signaling Technology, cat#2679, 1:800),
TSG101 (ESCRT-I Complex Subunit TSG101,
Sigma-Aldrich, cat# SAB2702167, 1:500). OS-EV
samples and as a control, protein from AT-MSCs
lysates, were denatured at 95°C for 5 min in redu-
cing Laemmli sample buffer, separated using Mini-
PROTEAN® TGX™ 4–20% gradient SDS-PAGE gel
(Bio-Rad) with page ruler prestained protein ladder
(Thermo Scientific) as a standard and blotted on
nitrocellulose membranes, 0.2 µm (#162–0112, Bio-
Rad). Blocking and antibody incubations were per-
formed in Odyssey blocking buffer (LI-COR) with
0.1% Tween-20. Membranes were probed with
IRDye® 800CW Goat anti-Mouse (LI-COR) at
1:15,000 for 2 hours at room temperature (RT).
After incubation, membranes were washed three
times in TBS-T for 10minutes at RT and imaged
on an Odyssey FC Imager (LI-COR).
EV treatments
MSCs and pre-osteoblast cells were plated in 24
well plates at a cell density of 2.5 −7.5x104 cells
per well, then treated with OS-EVs and analyzed
at time points 3, 7 and 14. Untreated MSCs and
pre-osteoblasts were used as controls. EVs were
added at day 1 (24h after cell adhesion), day 3
(48h after first dose) and day 5 (96h after first
dose) (Figure 1). On day 7, CM was collected and
cells were analyzed with methylation assays, flow
cytometry and quantitative real-time PCR (qRT-
PCR). MSCs treated with the same amount of auto-
logous EVs were used as an experimental control.
The experiments were repeated 4 times.
LINE-1 methylation analysis
DNA extraction was done using NucleoSpin®
Tissue XS (Macherey-Nagel, Ref 740,901).
Custom-made LINE-1 kit as described previously
[29] was used. Briefly, three areas inside the
LINE-1 promoter sequence and seven control
probes were included in the kit. 70ng of DNA
was used to perform MS-MLPA reaction using
the SALSA MS-MLPA Reagents kit P300-A1
Human DNA Reference-2 (MRC-Holland),
following a MS-MLPA standard reaction protocol
as described in MRC-Holland instructions
(http://www.mrc-holland.com). Methylation dos-
age ratio was calculated as described previously
[29]. Three controls were used; commercially
available colon cancer cell line RKO (ATCC®
CRL-2577), pooled blood sample from healthy
individual, and one unmethylated sample gener-
ated using GenomePlex complete whole genome
amplification (WGA) kit [29,30]. LINE-1 probes
and controls used in the analysis were received as
kind gift from Prof. Päivi Peltomäki (University
of Helsinki).
Methylation-specific multiplex
ligation-dependent probe amplification
(MS-MLPA)
The methylation status of tumour suppressor
genes were assessed using commercially available
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MS-MLPA kit (ME001-C2 and ME002-C1
Tumour suppressor, from MRC Holland) accord-
ing to the manufacturer’s instructions (http://
www.mrc-holland.com) using 150ng of DNA for
the analysis. The methylation dosage ratios (Dm)
were calculated as described previously [31].
A cut-off value of Dm ≥0.20 was considered to
indicate promoter methylation.
qRT-PCR
Total RNA was extracted from MSCs treated with
and without OS-EVs (n = 3) using miRCURY RNA
isolation kit (Cell and plant, Exiqon cat#300110).
RNA was reverse transcribed using High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher
Scientiﬁc). All PCR reactions were conducted in
triplicates in QuantStudio 5 (Applied Biosystems),
using TaqMan assays (Thermo Fisher Scientiﬁc).
The expression of the following genes was quantified:
intercellular adhesion molecule 1 (ICAM1, assay ID
Hs00164932_m1) matrix metallopeptidase 1 (MMP1,
assay ID Hs00899658_m1), runt-related transcrip-
tion factor 2 (RUNX2, assay ID Hs01047973_m1),
alkaline phosphatase, liver/bone/kidney (ALPL, assay
ID Hs01029144_m1), vascular endothelial growth
factor A, (VEGF-A, Hs00900055_m1), peroxisome
proliferator activated receptor gamma, (PPARγ,
Hs00234592_m1). Results were normalized with the
housekeeping gene, ribosomal protein lateral stalk
subunit P0 (RPLP0, assay ID Hs99999902_m1) and
calculated using the ddCt-method [32].
Flow cytometry analysis
MSCs receiving EV treatment (OS-EVs and MSC-
EVs) were analyzed with flow cytometry. Briefly,
MSCs and pre-osteoblasts with or without OS-EV
treatment, n = 3 with 3 repeats, as well as MSCs
receiving autologous EVs were analysed using BD
Accuri C6 flow cytometer (Becton Dickinson,
Franklin Lakes) using monoclonal antibodies con-
jugated with APC against CD54, CD73, CD106
(VCAM-1) (Clone 51-10C9) and CD271 (Clone
C40-1457). As controls, HOS-143b (n = 2),
U2OS (n = 1), BM-MSCs (n = 3) were analysed
using APC-conjugated monoclonal antibodies
against CD14, CD19, CD34, CD45RO, CD54,
CD73, CD90, CD105, CD106, CD271 and HLA-
DR, all purchased from BD PharmingenTM
(Becton Dickinson). Analysis was performed on
1 × 105 events per sample and positive expression
was defined as the level of fluorescence > 99% of
the corresponding unstained cell sample [26].
Statistical analysis
Statistical analyses were performed with GraphPad
Prism 6 (GraphPad Software Inc.) to analyse the
effects of OS-EVs on MSC. Cultures were analysed
using ANOVA two- way analysis of variance.
Bonferroni post-hoc tests were used to determine
individual significant differences. The results were
considered significant when the Bonferroni cor-
rected p-value was below 0.05.
Results
MSC displayed typical stem cell features and
osteogenic differentiation potential
In concordance with the guidelines defined by the
International Society for Cellular Therapy (ISCT),
the MSCs displayed characteristic morphology of
MSCs (Figure 2(a,b)) and also displayed the immu-
nophenotypical profile of MSCs (Figure 2(e)).
MSCs demonstrated a surface marker profile of
CD73/CD90/CD105 positive and CD14/CD19/
CD45/HLA-DR negative expression, also moderate
expression of CD34 was detected. Further, MSCs
also expressed moderate levels of CD54 (ICAM-1)
(Figure 2(e)). The osteogenic differentiation poten-
tial of MSCs was also evaluated by qALP and ARS.
The results showed that chemically induced osteo-
genesis enhanced the osteogenic differentiation and
mineralization process as compared to control con-
ditions (Figure 2(c,d,f)).
Characterization of OS-EVs
EVs were characterized using WB, TEM and NTA.
TEM revealed that the OS-EVs were intact and that
EVs of various shapes and sizes are secreted by OS
(Figure 3(a)). Western blotting results confirmed the
presence of EVs as all the EVmarkers (CD63, Hsp70,
and TSG101) showed the positive band, whereas
there was no band in calnexin, indicating the purity
of the EV samples (Figure 3(b)). According to the
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NTA results, the majority of the particles were in the
size range of 50–200 nm (Figure 3(c)) with a size
distribution range of approx. 50–500 nm (Figure 3
(d)). Particles between 50 and 400 nm in diameter
were termed as EVs. Distribution of particle fractions
is shown in Figure 3(e).
Treatment of MSCs with OS-EVs induced global
LINE-1 hypomethylation
Both MSCs and pre-osteoblasts were treated with
OS-EVs (+EVs) and analyzed at 0, 3, 7 and 14 to
examine the epigenetic effects induced by the
Figure 2. Morphological characterization of adipose-tissue derived mesenchymal stem cells (AT-MSCs) by light microscopy after
culturing in the maintenance media (MSCs; a) and osteogenic media (pre-osteoblasts; b) for 14 days. Scale bars are 100 μm. The level
of mineralization was assessed by Alizarin red staining in both non-treated AT-MSCs (MSC) (c) and osteogenically treated AT-MSCs
(pre-osteoblast) (d) after 14 days. (e) Surface marker expression (%) of undifferentiated AT-MSCs analyzed by flow cytometric
analysis. (f) Early osteogenic response measured by alkaline phosphatase (ALP) activity assay. Values are reported as mean ±SD and
the assay was performed at 7 and 21 days (**p < 0,05; n = 3) .
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treatments. Untreated (-EVs) MSCs and pre-
osteoblasts were used as control, and time point
0 served as a baseline with no treatment. As shown
in Figure 4(a), MSCs treated with OS-EVs exhib-
ited decreased LINE-1 expression at time point 3
which returned to baseline at time point 7, and
was maintained until time point 14 (time point 14
data not shown). For pre-osteoblasts (Figure 4(b)),
LINE-1 hypermethylation was seen at time points
3 and 7 and was also seen at time point 7 for the
control group (MSCs receiving autologous EVs).
Tumour suppressor genes methylation status
was not affected in MSCs treated with OS-EVs
To further investigate the epigenetic effects
mediated by OS-EVs treatment, methylation ana-
lysis of 29 tumour suppressor genes was
performed on both +EVs and -EVs MSCs and pre-
osteoblasts. The analyzed methylation status of the
genes investigated was not affected in MSCs and
pre-osteoblasts with +EV (data not shown).
Expression of MMP1, ICAM1, VEGF-A and RUNX1
was affected in MSCs treated with OS-EVs
Effect of OS-EV treatments was also evaluated on
gene expression level on both MSCs and pre-
osteoblasts (Figure 5). OS-EV treated MSCs and
pre-osteoblasts showed significantly elevated
expression of MMP1, ICAM1, and VEGF-A as
a response to OS-EV treatment (*p > 0.05).
However, EV treatment had a more pronounced
effect on MMP1 expression in MSCs when com-
pared to pre-osteoblasts. As expected, adipose mar-
ker PPARγ expression was reduced after OS-EV
Figure 3. OS-EVs characterization. (a) Confirmation of EVs by TEM. Scale bar 500 nm (b) Western blotting showed presence of EV
markers (TSG101, Hsp70 and CD63). Absence of calnexin protein indicate purity of the samples. (c–d) EV concentration and size
distribution analyzed by nanoparticle tracking analysis (NTA), y-axis depict particle concentration (particles 106/ml). PBS was used as
a negative control. (e) Table showing distribution of the particles, with D10, D50 and D90 representing the midpoint (D50) and range
(D10, D90) of the particle sizes of a given sample.
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treatment (**p > 0.001). Due to donor variation
ALPL and RUNX2 showed no heterogeneous gene
expression.
Surface marker expression analysis
Surface marker expression was also assessed in MSCs
and pre-osteoblast +EVs and -EVs (Table 1). AT-
MSCs treated with autologous MSCs (+autoEVs),
osteosarcoma cell lines (HOS143b and U2OS) as
well as BM-MSCs were added as controls for marker
expression. The flow cytometric analysis showed
(Figure 6(a)) that the only marker affected by the
treatment was CD54 (ICAM1). A relative dose speci-
fic response was detected, as no change in CD54
expression level was seen at lowest OS-EV concentra-
tion (5×104), and at an intermediate concentration
(4×105), higher expression was seen at highest dose
(1×107particles) (Figure 6 (a,b)). In addition CD106
(Vascular cell adhesion protein 1, VCAM-1) was ana-
lyzed, which is differentially expressed in AT-MSCs
(negative), and BM-MSCs (positive) and reportedly
present in rat osteosarcoma cell line COS1NR [33,34].
The results showed that VCAM-1 was expressed at
moderate levels only in BM-MSCs, with no expres-
sion detected in AT-MSCs. Next, CD271 (low-affinity
nerve growth factor receptor, LNGFR) was analyzed
which is reportedly present in osteosarcoma stem cells
[35,36]. The data showed that CD271 was present
only in U2OS control cells, with moderate expression
present in BM-MSCs and no expression detected in
AT-MSCs.
Discussion
It is well known that the tumour microenvironment
is correlated with tumorigenesis and cancer pro-
gression. MSCs have been reported to be isolated
at high frequency from OS samples demonstrating
their importance in the OS microenvironment [37].
In recent years, EVs have shown to be powerful
mediators of intercellular communication with the
ability to manipulate the local and systemic
tumour microenvironment [17,38,39]. Having
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a bimodal role in tumorigenesis, EVs modulate
either immunostimulatory or inhibitory functions
or both [40]. The balance between these two
responses is therefore likely to be the determining
factor for the outcome of disease. EVs are therefore
an excellent tool for studying the interaction
between the tumour and its surrounding cells.
Cross-talk between MSCs and OS has demon-
strated the oncogenic potential of OS-EVs in reci-
pient cells [37,41,42]. For example, in an in vivo
mouse study, OS-EVs carrying functional TGFβ
(transforming growth factor β) were internalized
by MSCs and altered the MSCs phenotype towards
a pro-tumorigenic and pro-metastatic phenotype
by activating oncogenic IL&-STAT3 signalling
pathways, thereby promoting tumour growth and
metastasis [21]. In recent years, the composition of
OS-EVs cargo has been investigated, indicating the
presence of proteins related to tumour progression
and metastasis [43,44], and the presence of
repetitive DNA, including satellites and transposa-
ble elements [45]. However, the impact of OS-EVs
on the epigenome of MSCs is still unclear and the
consequences of these interactions and their
impact on tumour behaviour need to be addressed.
Based on the reported evidence at genetic level,
OS-EVs alter the MSC physiology, thus, this study
addressed the implications of OS-EVs in the epi-
genetic reprogramming of MSCs.
To date, there is no consensus about EV dose
required in cell culture and animal model
experiments. EV concentrations reported in lit-
erature are not clearly stated and there is also
considerable variation with regards to the
experimental setup and the cell line studied.
Since the concentrations for EV treatments are
not standardized, we tested several EV concen-
trations to determine dose-dependent effect of
OS-EVs. Methylation and flow cytometric ana-
lysis were performed with different EV
Table 1. Surface marker expression of MSCs and pre-osteoblast untreated or treated with OS-EVs (-EVs/+EVs), n = 3 repeated 3
times. As controls, MSCs treated with autologous EVs, as well as cell lines (HOS143b, U2O and BM-MSCs) were used. CD, cluster of
differentiation.
OS-EV treatment group Controls
MSC
-EVs MSC +EVs
Pre-osteo
-EVs
Pre-osteo
+EVs
MSC +autoMSC EVs
(n = 3)
HOS143b
(n = 2)
U2OS
(n = 1)
BM-MSC
(n = 3)
CD14 0.3 ± 0.1 0.2 0.3. ± 0.1
CD19 0.2 ± 0.1 0.1 0.1. ± 0.1
CD34 2.2 ± 2.8 0.2 1.1. ± 1.7
CD45 0.4 ± 0.2 0.3 0.3 ± 0.1
CD54 27.6 ± 19.1 46.7 ± 38.4 50.0 ± 8.8 79.4 ± 6.1 7.2 ± 0.45 99.7 ± 0.7 5.9 12.6 ± 2.3
CD73 98.1 ± 2.6 98.8 ± 1.9 99.5 ± 0.2 99.7 ± 0.1 98.0 ± 0.7 99 ± 1.2 0.4 99.4 ± 0.4
CD90 4 ± 4.1 99 97.6 ± 0.0
CD105 97.7 ± 0.9 37.1 96.6 ± 1.2
HLA-DR 0.9 ± 0.3 0.5 1.3 ± 0.4
CD106 0.1 ± 0.1 0.6 ± 0.7 0.3 ± 0.2 0.3 ± 0.2 0.1 ± 0.7 0 0.2 41.4
CD271 0.0 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 1.9 86.9 24.5
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Figure 6. (a) Surface marker ICAM/CD54 expression measured by flow cytometry for MSCs untreated and treated with OS-EVs. X-axis
depict OS-EVs concentrations. Dotted line represents baseline measurement (MSCs untreated with OS-EVs). (b) Table showing
repeats and amount of OS-EVs applied per MSC.
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concentrations to set up a dose-response pat-
tern, however due to lack of material gene
expression was repeated only with one EV con-
centration. LINE-1 analysis was not affected by
different EV doses, however CD54 expression
by flow cytometry showed a dose-dependent
response.
The complex bioactive cargo of EVs, including
molecules with epigenetic reprogramming capability,
has been reported to induce an epigenetic response
in recipient cells by affecting their methylation sta-
tus, thereby promoting genomic instability [46].
Moreover, since subtle changes in the microenviron-
ment can stimulate the transformation of cells, we
applied OS-EVs to introduce the first hit of transfor-
mation for MSCs in to order to investigate whether
OS-EVs affect the global LINE-1 methylation status
of MSCs. Secondly, the study was set out to analyze
whether MSCs or pre-osteoblasts are susceptible to
epigenetic reprogramming, potentially highlighting
the cell type directing sarcomagenesis.
Our data indicated that a significant decline in
LINE-1 methylation occurred in MSCs after 3 days
of induction with OS-EVs which was maintained
until day 7, but returned to normal levels after
extended exposure to OS-EVs (time point 14; data
not shown), concluding that epigenetic regulation
appears to play a role in transformation of MSCs.
On the contrary, LINE-1 hypomethylation was not
observed in pre-osteoblasts treated with OS-EVs
(Figure 4), indicating that pre-osteoblasts are less
susceptible to global LINE-1 hypomethylation. In
addition, our data indicated that hypomethylation
occurs early during the transformation of MSCs
and subsequently, as the methylation levels return
to normal level after extended exposure to OS-EVs,
several oncogenic hits may be required for main-
tenance of hypomethylation and full transformation
of MSCs. Transformation of normal cells is
a multistep process, which is linked to accumula-
tion of genetic and epigenetic alterations. To
address the timing of genome-wide methylation
and to determine whether it is causative for the
transformation of MSCs, Wild and co-authors
[47] developed a model for producing fully trans-
formed MSCs by introducing five consecutive
oncogenic hits, concluding that in vitro transforma-
tion of MSCs induces gradual hypomethylation and
it is not causative for transformation. The
discrepancy between our results and those of Wild
et al may be explained by several factors, such as
different methods used for MSC transformation,
the fact that LINE-1 methylation was studied only
at late stage of MSC transformation by Wild et al in
contrast to our study. However, it should be noted
that the actual epigenetic changes occurring during
the in vivo transformation may not recapitulate in
a simplified cell model.
The cell of origin for OS is presumed to be an
intermediate precursor between MSCs and osteo-
blasts [48]. In our study, under the influence of
environmental signals, i.e., OS-EV treatment, epi-
genetic modifications underpin the transformation
of MSCs but not of pre-osteoblasts, however, con-
clusions regarding the cell of origin is difficult to
draw with our limited data.
As global hypomethylation is known to affect
genome-wide methylation levels [46,49], our study
further evaluated whether OS-EVs may regulate
the promotor hypermethylation status of
tumour suppressor genes. The methylation status
of the 29 tumour suppressor genes was not
affected by the treatment with OS-EVs, indicating
that short term exposure of the MSCs to OS-EVs
was not sufficient to induce promotor hyper-
methylation of the selected genes and that this
event occurs at a later stage of transformation.
Global LINE-1 hypomethylation contribute to
cancer development by inducing genetic instabil-
ity, and predisposing the cells to chromosomal
defects, transcription disruption, insertion muta-
tions, and thus influencing the overall gene expres-
sion [50–52]. OS-EV treated cells have been shown
to acquire tumour-phenotype characteristics such
as increased adhesion, proliferation, migration
rate, and anchorage-independent growth [42].
Subsequently, the effects of OS-EVs on recipient
cells were investigated by focusing on analyzing
the expression of genes (MMP1, VEGF-A,
ICAM1) related only to bone microenvironment
remodelling. Both MSCs and pre-osteoblasts
showed higher expression of these genes after OS-
EV treatment (Figure 6). Matrix metalloprotei-
nase-1 (MMP1) is involved in extracellular matrix
(ECM) remodelling, regulation of cell signalling in
bone microenvironment, and in facilitating inva-
sion and metastasis [53]. Its high expression is
related to poor prognosis in OS patients [54].
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Binding of vascular endothelial growth factor
(VEGF-A) to its receptor results in the expression
of MMPs, which subsequently allows for ECM
degradation and formation of new vessels. Thus,
overexpression of VEGF-A in OS is associated with
lung metastasis and poor overall survival [55].
Intercellular adhesion molecule 1 (ICAM1/CD54)
is an adhesion molecule that regulates inflamma-
tion, immune response, and intercellular signalling
[56,57]. It is expressed in many cancers and facil-
itates cancer cell invasion through the ECM.
Increased expression of ICAM1 is also reported
in OS cells co-cultured with MSCs [37]. This result
is further supported by protein level data analyzed
by flow cytometry. Taken together, these results
indicate, that MSCs may have transformed
towards a cancer associated fibroblast phenotype
by the OS-EVs treatment.
Numerous in vitro investigations have demon-
strated that fat-induction factors such as PPARγ inhi-
bit osteogenesis, and conversely, bone-induction
factors such as RUNX2 deter adipogenesis [58]. The
expression of osteogenesis (RUNX2 and ALPL) and
adipogenesis (PPARγ) related genes was assessed in
our study. The expression of all genes was elevated by
osteogenic conditions when compared with the con-
trol, but OS-EV treatment provided a unique signa-
ture to the regulation of the genes. OS-EVs
upregulated the expression of RUNX2, conversely
ALPL and PPARγ were downregulated in response
to OS-EV treatment (Figure 6). Specifically, the
TGFβ/BMPs signalling pathway is known to have
dual roles in regulating adipogenic and osteogenic
differentiation of MSCs, as expression of RUNX2
and PPARγ can be regulated by either the Smad or
the p38 MAPK pathway, depending on the composi-
tion and concentration of signalling cues in the
microenvironment [58]. Therefore, as our results
show the upregulation of RUNX2 in MSCs promoted
osteogenesis, while inhibiting adipogenesis, shown by
the expression of PPARγ. OS cells are known to share
many features with osteoprogenitors, such as expres-
sion of osteogenic markers (RUNX2, ALPL).
Furthermore, the more aggressive OS phenotypes
often resemble early osteoprogenitors, while less
aggressive tumours appear to share similarities with
osteogenic MSCs that have progressed further along
the differentiation cascade. For instance, ALPL shows
lower expression in OS tumour cells compared to
committed osteoblastic cell line [59], a trend also
seen in our ALPL expression results. However, our
results may be inadequate to prove the full commit-
ment of MSCs into a transformed phenotype, but
point towards MSCs being primed by the cargo pre-
sent in the OS-EV vesicle fraction.
There is yet very little data on the concentration
of EVs needed for a cell response or a therapeutic
effect, so we studied the concentration of OS-EV
vesicles given based on surface marker expression,
and we found that ICAM1/CD54 is expressed in
a dose dependent manner. The response is likely
primarily an immune response, however, it is not
excluded that it is associated with MSCs present-
ing a transformed phenotype.
Conclusions
Our study investigated the effects induced by OS-
EVs on MSCs and revealed a number of significant
findings. Firstly, we showed for the first time that
OS-EVs are implicated in epigenetic reprograming of
MSC and that the transformation of MSCs, but not
pre-osteoblasts, is epigenetically regulated via global
LINE-1 hypomethylation; secondly, the study
demonstrates the oncogenic power of OS-EVs on
MSCs gene expression related to bone microenviron-
ment remodelling, and lastly, we saw a dose-
dependent effect of OS-EVs on adhesion molecule
expression ICAM1/CD54 in MSCs. Additional stu-
dies are needed to investigate the elements responsi-
ble for global LINE-1 hypomethylation in OS-EVs,
and for identifying the mechanisms by which LINE-1
hypomethylation affects MSC behaviour.
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